Episurf forms a new strategic business segment through the acquisition of real estate assets. The purchase price of SEK up to 1,147 million is partly paid through shares, convertibles and warrants

Episurf agreed to acquire a holding company that owns and is set to acquire a combined portfolio of 13 Swedish properties (aggregate agreed underlying property value ~SEK 743m, annual rental income ~SEK 66m, NOI ~SEK 52m, yield ~7.2%, economic occupancy ~97%) and manages SEK 700m nominal senior unsecured green bonds, for a preliminary purchase price of ~SEK 1,147m. Consideration will be paid via promissory notes (interest STIBOR 3m + 3.25%), with roughly SEK 797m short‑term obligations (H1 2026) to be settled by SEK 420m cash and SEK 377m in Class B shares/convertibles at SEK 0.045, plus warrants tied to a 2029 note conversion mechanism; the financing structure could dilute existing shareholders by up to ~1,208%. Completion is subject to a First Extraordinary General Meeting in early Feb 2026 and bondholder approvals, and the transaction triggers a Nasdaq Stockholm re-listing process due to material changes in operations.

Analysis

Market structure: Episurf’s pivot creates two clear winners — the Seller/real-estate consortium (shielded from cash payment via equity) and holders of Swedish yielding property assets if bank financing is secured — and clear losers: existing EPIS B equity holders face immediate dilution risk up to ~1,208% and a potential market re-rating. The deal transfers valuation risk from an illiquid medtech R&D story to a cash-flowing property portfolio (SEK 743m underlying, NOI SEK 52m, implied yield 7.2%), compressing Episurf’s medtech growth optionality and concentrating NAV on real estate pricing and financing execution.

Risk assessment: Key tail risks are (1) bondholder vote failure or IB Invest written-procedure rejection (next 30–60 days) reverting the deal, (2) EGM rejection (First EGM H1 Feb 2026) triggering reversal, and (3) inability to finance the Non-completed Portfolio by Mar 2026. Rate risk matters: promissory notes at STIBOR 3M +3.25% and warrants/conversion mechanics create leverage to short-term rate moves and to share-price volatility; operationally, average lease tenor 2.7 years concentrates rollover risk.

Trade implications: Immediate actionable short bias on EPIS B (equity and/or 3–6 month puts) to capture dilution and listing-risk repricing ahead of the EGM; hedge by going long high-quality Swedish listed real-estate (e.g., CAST.ST, CATE.ST) to capture flight-to-quality at 1–2% NAV each. Use put spreads to cap cost and size shorts to 1–3% NAV given borrow/liquidity constraints; reprice trades after EGM outcome or bond vote within 30–60 days.

Contrarian angle: The market may over-penalize the asset transfer if the property financing closes — if audited cash flows validate NOI SEK 52m and net leverage ~0.44 (330m debt on 743m value), EPIS could trade as a mispriced net-asset play post-integration. A conditional small long (0.5–1% NAV) should be considered only if post-EGM disclosures show secured financing and a verified property NAV > SEK 700m and float >20%, otherwise downside dominates.

Key Decisions for Investors

• Establish a tactical short on Episurf (EPIS B) equal to 1–2% of NAV via borrowed shares or purchase 3–6 month put spreads (buy 0.03 strike, sell 0.015 strike) within 48 hours to capture dilution and listing/EGM risk; target profit 50–70%, stop-loss 30% above entry, exit or re-assess immediately after the First Extraordinary General Meeting (H1 Feb 2026).
• Allocate 1% NAV each to long positions in Swedish high-quality REITs Castellum (CAST.ST) and Catena (CATE.ST) with a 6–12 month horizon to harvest yield rotation into stable property cash flows; set protective stops at 12% and target total return of 10–25% if market re-rates real estate exposure.
• Buy a defensive, low-cost hedge: 6-month put spread on EPIS B (buy nearer-term put, sell lower strike) sized to offset 50% of the short equity position’s max loss; roll or unwind after bond Written Procedure and EGM outcomes (30–60 day catalyst window).
• Do NOT initiate new long positions in small-cap medtechs with comparable balance-sheet stress; redeploy 2–3% of such allocations into select Swedish property equities or short-duration cash substitutes until Episurf’s post-EGM capital structure and audited property financing are publicly confirmed (threshold: financing secured by end of Mar 2026).